Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec”

Design Therapeutics, Inc. (NASDAQ:DSGN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. A caller asked for Cramer’s thoughts on the company, and here’s what he had to say:

Pure spec, pure spec. Understand, you can lose everything, or you can double on that one. I don’t know which it’s going to be. That’s the problem.

A stock market graph. Photo by energepic.com

Design Therapeutics, Inc. (NASDAQ:DSGN) is a clinical-stage biopharmaceutical company that develops small-molecule drugs to treat inherited genetic diseases caused by nucleotide repeat expansion. The company uses its proprietary platform, GeneTAC, to create potential treatments for conditions such as Friedreich’s Ataxia, Huntington’s Disease, and other progressive neuromuscular and neurodegenerative disorders.

While we acknowledge the risk and potential of DSGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DSGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 1759070 - 1